Literature DB >> 18779804

Cost/success projections for US biodefense countermeasure development.

Jason Matheny, Michael Mair, Bradley Smith.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18779804     DOI： 10.1038/nbt0908-981

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  5 in total

1.  BARDA's budget.

Authors:  Lynn C Klotz; Alan Pearson
Journal:  Nat Biotechnol       Date:  2009-08       Impact factor: 54.908

2.  Sublethal staphylococcal enterotoxin B challenge model in pigs to evaluate protection following immunization with a soybean-derived vaccine.

Authors:  Laura C Hudson; Brynn S Seabolt; Jack Odle; Kenneth L Bost; Chad H Stahl; Kenneth J Piller
Journal:  Clin Vaccine Immunol       Date:  2012-10-31

3.  FDA Experience with Medical Countermeasures under the Animal Rule.

Authors:  Paul Aebersold
Journal:  Adv Prev Med       Date:  2011-09-20

4.  Development of an in vitro potency assay for anti-anthrax lethal toxin neutralizing antibodies.

Authors:  Gail Whiting; Michael Baker; Sjoerd Rijpkema
Journal:  Toxins (Basel)       Date:  2012-01-19       Impact factor: 4.546

5.  Biodefense: trends and challenges in combating biological warfare agents.

Authors:  George P Tegos
Journal:  Virulence       Date:  2013-11-14       Impact factor: 5.882
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.